Rituximab success paves way for plant produced mAbs In-PharmaTechnologist.com iBio is expanding use of its green plant technology to biosimilar mAbs after producing rituximab using the system. Producing rituximab, marketed as Mabthera, using non-transgenic green plants expands the system's use beyond ... |
